{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:10:46Z","timestamp":1793326246330,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European Alliance of Associations for Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ard.2026.01.023","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:04:10Z","timestamp":1773378250000},"page":"991-1009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update"],"prefix":"10.1016","volume":"85","author":[{"given":"Josef S.","family":"Smolen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Konzett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faidra","family":"Laskou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimme L.","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Mateus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Primdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savia","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Alvaro-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya H.","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Codreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Haavardsholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Iagnocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Antonie","family":"Juge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke Helene","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Po\u00f3r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel dos Santos","family":"Sobrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russka","family":"Shumnalieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Senolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Silva-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Turesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"van Duuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.\u202fM.","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ard.2026.01.023_bib0001","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ard.2026.01.023_bib0002","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8930","key":"10.1016\/j.ard.2026.01.023_bib0003","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ard.2026.01.023_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ard.2026.01.023_bib0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0006","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1002\/art.21298","article-title":"Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial","volume":"52","author":"Svensson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.01.023_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ard-2023-224270","article-title":"Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?","volume":"83","author":"van Ouwerkerk","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.01.023_bib0008","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0009","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2026.01.023_bib0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"Suppl 39","key":"10.1016\/j.ard.2026.01.023_bib0011","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0012","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"82","author":"Studenic","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10055","key":"10.1016\/j.ard.2026.01.023_bib0014","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9870","key":"10.1016\/j.ard.2026.01.023_bib0016","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ard.2026.01.023_bib0017","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/annrheumdis-2018-213271","article-title":"Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2026.01.023_bib0018","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/ard-2023-224476","article-title":"Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial","volume":"82","author":"Lillegraven","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0019","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.01.023_bib0020","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/annrheumdis-2011-200990","article-title":"EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis","volume":"71","author":"Gerlag","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.01.023_bib0021","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2012-202967","article-title":"Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study)","volume":"73","author":"van Aken","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.01.023_bib0022","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.01.023_bib0023","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ard.2025.05.027","article-title":"Abatacept in individuals at risk of developing rheumatoid arthritis: results from the arthritis prevention in the pre-clinical phase of RA with abatacept long term outcomes (ALTO) study","volume":"84","author":"Cope","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.01.023_bib0024","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ard.2025.05.327","article-title":"Long-term prevention of RA in high-risk individuals after a 6-month placebo-controlled intervention with abatacept- the ARIAA trial","volume":"84","author":"Tascilar","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0025","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2026.01.023_bib0026","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.01.023_bib0027","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0029","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0031","unstructured":"EULAR. EULAR SOPs standard operating procedures for task forces 2024. Available from: https:\/\/www.eular.org\/web\/static\/lib\/pdfjs\/web\/viewer.html?file=https:\/\/www.eular.org\/document\/download\/1288\/44fd21f5-69ff-449e-a959-c1398468bfe1\/1198. Accessed August 26, 2025"},{"issue":"18","key":"10.1016\/j.ard.2026.01.023_bib0032","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0033","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0034","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0035","unstructured":"Konzett VLF, Smolen JS, Edwards CJ, Aletaha D, van der Heijde D, Winthrop KL, et al. Efficacy of synthetic and biological DMARDs and glucocorticoids: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. submitted"},{"issue":"6","key":"10.1016\/j.ard.2026.01.023_bib0036","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ard.2026.02.024","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"85","author":"Laskou","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0037","unstructured":"Medicine. CfEB. Oxford Centre for Evidence-Based Medicine: levels of evidence (March 2009). Available from:https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 2011. Accessed March 3, 2025."},{"issue":"6","key":"10.1016\/j.ard.2026.01.023_bib0038","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0039","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2021-222020","article-title":"2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases","volume":"82","author":"Gwinnutt","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.01.023_bib0040","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/acr.22583","article-title":"Distinctions between diagnostic and classification criteria?","volume":"67","author":"Aggarwal","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ard.2026.01.023_bib0041","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/annrheumdis-2012-202779","article-title":"EULAR definition of erosive disease in light of the 2010 ACR\/EULAR rheumatoid arthritis classification criteria","volume":"72","author":"van der Heijde","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.01.023_bib0042","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/ard.2003.009548","article-title":"Doppler ultrasound findings in healthy wrists and finger joints","volume":"63","author":"Terslev","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0043","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/annrheumdis-2015-208103","article-title":"Prevalence of ultrasound synovial inflammatory findings in healthy subjects","volume":"75","author":"Padovano","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ard.2026.01.023_bib0044","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.7863\/ultra.33.12.2087","article-title":"Sonographic assessment of healthy peripheral joints: evaluation according to demographic parameters","volume":"33","author":"Machado","year":"2014","journal-title":"J Ultrasound Med"},{"issue":"4","key":"10.1016\/j.ard.2026.01.023_bib0045","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.20135","article-title":"Magnetic resonance imaging of wrist and finger joints in healthy subjects occasionally shows changes resembling erosions and synovitis as seen in rheumatoid arthritis","volume":"50","author":"Ejbjerg","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0046","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-018-1667-z","article-title":"Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial","volume":"20","author":"Stamm","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.ard.2026.01.023_bib0047","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2026.01.023_bib0048","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-019-0279-6","article-title":"Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets","volume":"15","author":"Aletaha","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2026.01.023_bib0049","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/art.39714","article-title":"Brief report: estimating disease activity using multi-biomarker disease activity scores in rheumatoid arthritis patients treated with abatacept or adalimumab","volume":"68","author":"Fleischmann","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.01.023_bib0050","doi-asserted-by":"crossref","first-page":"m4328","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0051","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/ar4491","article-title":"Remission in rheumatoid arthritis: benefit over low disease activity in patient reported outcomes and costs","volume":"16","author":"Radner","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.ard.2026.01.023_bib0052","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/annrheumdis-2015-208941","article-title":"Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial","volume":"75","author":"Dale","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0053","doi-asserted-by":"crossref","first-page":"i4205","DOI":"10.1136\/bmj.i4205","article-title":"Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial","volume":"354","author":"Haavardsholm","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ard.2026.01.023_bib0054","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jama.2018.21362","article-title":"Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis: the IMAGINE-RA randomized clinical trial","volume":"321","author":"M\u00f8ller-Bisgaard","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ard.2026.01.023_bib0055","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ard.2025.06.412","article-title":"POS1058\u2005Discordant pain patterns in rheumatoid arthritis patients achieving inflammatory control: analysis of clinical trial data from 7 randomized controlled trials","volume":"84","author":"Kerschbaumer","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.01.023_bib0056","first-page":"575","article-title":"Interpretation and power of a pooled index","volume":"20","author":"Goldsmith","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2026.01.023_bib0057","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.01.023_bib0058","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard.51.2.177","article-title":"Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis","volume":"51","author":"van der Heijde","year":"1992","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.01.023_bib0059","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.62.5.482","article-title":"Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis","volume":"62","author":"Aletaha","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0060","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.7326\/ANNALS-24-01598","article-title":"Long-term routine laboratory toxicity monitoring of immunomodulatory drugs in rheumatoid arthritis: a retrospective cohort study","volume":"178","author":"Ulijn","year":"2025","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ard.2026.01.023_bib0061","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0062","article-title":"When less is more, none can be even better: rethinking routine follow-up of chronic disease exemplified with rheumatoid arthritis","author":"Brkic","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0063","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","article-title":"Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2026.01.023_bib0064","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s10067-022-06221-z","article-title":"Oral methotrexate at doses 15-25 mg\/week is non-inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2026.01.023_bib0065","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0066","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1007\/s10067-025-07646-y","article-title":"Split vs single-dose oral methotrexate in rheumatoid arthritis: a randomized controlled trial (SMART study)","volume":"44","author":"Prasad","year":"2025","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0067","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","article-title":"Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial","volume":"74","author":"Verschueren","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0068","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ard.2025.03.002","volume":"84","author":"Hetland","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0069","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/acr.23759","article-title":"Low persistence rates in patients with rheumatoid arthritis treated with triple therapy and adverse drug events associated with sulfasalazine","volume":"71","author":"Erhardt","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.ard.2026.01.023_bib0070","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/ard.2006.066662","article-title":"Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score","volume":"66","author":"van der Kooij","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.01.023_bib0071","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004535","article-title":"Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial","volume":"10","author":"Bertrand","year":"2024","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.ard.2026.01.023_bib0072","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard-2022-222835","article-title":"After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries","volume":"82","author":"Pombo-Suarez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0073","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ard.2025.03.015","article-title":"Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial","volume":"84","author":"Wientjes","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2026.01.023_bib0074","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial","volume":"42","author":"Matteson","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.01.023_bib0075","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0076","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ard.2026.01.023_bib0077","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.01.023_bib0078","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","article-title":"EULAR revised recommendations for the management of fibromyalgia","volume":"76","author":"Macfarlane","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2026.01.023_bib0079","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.01.023_bib0080","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","article-title":"Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update","volume":"84","author":"Nash","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.01.023_bib0081","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/ard-2022-222784","article-title":"Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update","volume":"82","author":"Aletaha","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0082","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-024-03375-w","volume":"26","author":"Leng","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.ard.2026.01.023_bib0083","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40261-025-01453-8","article-title":"Efficacy and safety of biosimilar CT-P47 versus reference tocilizumab: 1-year results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis","volume":"45","author":"Burmester","year":"2025","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0084","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mayocp.2023.08.029","article-title":"Real-World clinical equivalence of generic and branded tofacitinib: a prospective longitudinal cohort study in patients with rheumatoid arthritis","volume":"99","author":"Zhao","year":"2024","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.ard.2026.01.023_bib0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.mayocp.2023.11.014","article-title":"Generic tofacitinib-A more affordable JAK inhibitor","volume":"99","author":"Goll","year":"2024","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.ard.2026.01.023_bib0086","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ard.2026.01.023_bib0087","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ard.2025.01.024","article-title":"Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statement","volume":"84","author":"Konzett","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0088","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ard.2025.05.014","article-title":"Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register","volume":"84","author":"Schaefer","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0089","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ard.2025.08.028","article-title":"Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease","volume":"85","author":"Giles","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.023_bib0090","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/art.43199","article-title":"Three-year results of tapering tumor necrosis factor inhibitor to withdrawal compared to stable tumor necrosis factor inhibitor among patients with rheumatoid arthritis in sustained remission: a multicenter randomized trial","volume":"77","author":"Kj\u00f8rholt","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.01.023_bib0091","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"37","key":"10.1016\/j.ard.2026.01.023_bib0092","first-page":"46","article-title":"Immunological tolerance in the therapy of rheumatoid arthritis","volume":"7","author":"van de Ven","year":"2007","journal-title":"Discov Med"},{"issue":"20","key":"10.1016\/j.ard.2026.01.023_bib0093","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160964","article-title":"Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide\/calcitriol liposomes in ACPA+ rheumatoid arthritis","volume":"7","author":"Sonigra","year":"2022","journal-title":"JCI Insight"},{"issue":"10271","key":"10.1016\/j.ard.2026.01.023_bib0094","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ard.2026.01.023_bib0095","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ard.2026.01.023_bib0096","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/annrheumdis-2019-215987","article-title":"Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab","volume":"79","author":"Shafran","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.01.023_bib0097","first-page":"999","article-title":"Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis","volume":"42","author":"Mart\u00ednez-Feito","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.01.023_bib0098","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40744-025-00769-3","article-title":"Influence of rheumatoid factors on the efficacy of TNF inhibitor therapy in patients with rheumatoid arthritis","volume":"12","author":"Nagayasu","year":"2025","journal-title":"Rheumatol Ther"},{"issue":"5","key":"10.1016\/j.ard.2026.01.023_bib0099","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/annrheumdis-2013-203765","article-title":"Development of healthcare quality indicators for rheumatoid arthritis in Europe: the eumusc.net project","volume":"73","author":"Petersson","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:17:00Z","timestamp":1780323420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003496726000750"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.01.023","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}